Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 123.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 14.64M |
| Shares Out | 59.88M |
| EPS (ttm) | 0.21 |
| PE Ratio | 9.71 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,779,545 |
| Open | 2.000 |
| Previous Close | 4.100 |
| Day's Range | 1.430 - 2.150 |
| 52-Week Range | 1.430 - 5.170 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+506.8%) |
| Earnings Date | Nov 12, 2025 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 506.80% from the latest price.
News
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript
Eledon Pharmaceuticals, Inc. ( ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros -...
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The comp...
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart de...
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at Kidney Week
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m 2 post-transplant for patients on tegoprubart Company on track to report topline...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function...
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6...
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at WTC 2025
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginn...
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transpla...
Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering potential investment ideas and sparking community discussion. Aeluma, Inc. is a speculative microcap with game-changing se...
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positi...
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transpl...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updat...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini...
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, u...
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its commo...
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose cont...